Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Completed 3Terminated 1

Sponsor Class

OTHER 34INDUSTRY 4OTHER_GOV 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 13Gastrointestinal 13Other solid neoplasm 6Head & Neck 4Breast 4Sarcoma 2Lymphoid 2Gynecologic 2Tumor-Agnostic 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2Gastrointestinal Neoplasms 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × camrelizumab × Breast × Clear all
NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
441 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Terminated
80 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
99 enrolled
BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
32 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡